Survival and sudden cardiac death after septal ablation for hypertrophic obstructive cardiomyopathy
Key result
Percutaneous transluminal septal myocardial ablation was associated with similar 5-year survival compared to an HCM control cohort (83% vs 79%; P=0.8).
Why the study?
Does percutaneous transluminal septal myocardial ablation (PTSMA) affect long-term survival and the risk of sudden cardiac death in patients with hypertrophic obstructive cardiomyopathy compared to a control cohort with hypertrophic cardiomyopathy?
Population
167 patients, comprising 77 with hypertrophic obstructive cardiomyopathy and a control cohort of 90 patients…
Comparison
Percutaneous transluminal septal myocardial… vs Control cohort of patients with hypertrophic…
Design
Cohort
Follow-up
3.5 ± 2.8 years
Authors
Discussion
Loading...
Member takes
Implication
PTSMA supports procedural safety in HOCM; leaves open randomized trials to confirm survival benefit versus controls.
Study Design
Type
Cohort (n=167)
Structured PICO
Does percutaneous transluminal septal myocardial ablation (PTSMA) affect long-term survival and the risk of sudden cardiac death in patients with hypertrophic obstructive cardiomyopathy compared to a control cohort with hypertrophic cardiomyopathy?
P
Population
167 patients with hypertrophic cardiomyopathy, including 77 treated with percutaneous transluminal septal myocardial ablation and 90 controls, followed for a mean of 3.5 years.
E
Exposure
Percutaneous transluminal septal myocardial ablation (PTSMA)
C
Comparator
Control cohort of patients with hypertrophic cardiomyopathy (HCM)
O
Outcome
Long-term survival and survival free of sudden cardiac death (SCD) at 5 yearshard clinical
Main Result
Absolute Event Rate: 83% vs 79%
p-value: p=0.8
PTSMA for hypertrophic obstructive cardiomyopathy is associated with similar long-term survival and risk of sudden cardiac death compared to a control cohort of patients with hypertrophic cardiomyopathy.
Cite This Study
Jensen et al. (2011) conducted a cohort in hypertrophic obstructive cardiomyopathy (HOCM) (n=167). percutaneous transluminal septal myocardial ablation (PTSMA) vs. hypertrophic cardiomyopathy (HCM) control cohort was evaluated on five years survival (p=0.8). Percutaneous transluminal septal myocardial ablation was associated with similar 5-year survival compared to an HCM control cohort (83% vs 79%; P=0.8).